Metastatic Renal Cell Carcinoma

Oncology
18
Pipeline Programs
14
Companies
16
Clinical Trials
2 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
7
0
1
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
583%
Monoclonal Antibody
117%
+ 12 programs with unclassified modality

On Market (5)

Approved therapies currently available

Novartis
AFINITORApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2009
Novartis
AFINITOR DISPERZApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2012
U
EVEROLIMUSApproved
everolimus
Unknown Company
oral2025
U
PROLEUKINApproved
aldesleukin
Unknown Company
Lymphocyte Growth Factor [EPC]intravenous1992
Novartis
ZORTRESSApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2010

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
2
AldesleukinPhase 41 trial
EverolimusPhase 41 trial
Active Trials
NCT00414765Completed26Est. Mar 2010
NCT01266837Completed64Est. Oct 2017
IB
Immatics BiotechnologiesGermany - Munich
1 program
1
SunitinibPhase 3Small Molecule1 trial
Active Trials
NCT01265901Completed339Est. Jul 2015
Pfizer
PfizerNEW YORK, NY
3 programs
2
AxitinibPhase 2Small Molecule1 trial
PF-04856884Phase 22 trials
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaN/A1 trial
Active Trials
NCT04919122Active Not Recruiting468Est. Dec 2026
NCT05817903Recruiting118Est. Apr 2027
NCT01441414Terminated18Est. Mar 2014
+1 more trials
Astellas
AstellasChina - Shenyang
2 programs
2
AGS-16C3FPhase 21 trial
TivozanibPhase 2Small Molecule1 trial
Active Trials
NCT02639182Completed133Est. Oct 2020
NCT01673386Terminated58Est. Jan 2014
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
EnzastaurinPhase 21 trial
Active Trials
NCT00709995Completed17Est. Sep 2018
Providence Therapeutics
1 program
1
HD IL2Phase 21 trial
Active Trials
NCT00554515CompletedEst. Oct 2013
CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
1 program
1
Panzem® NCDPhase 21 trial
Active Trials
NCT00444314CompletedEst. Oct 2009
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT01136733Completed173Est. Feb 2018
Lantheus Medical Imaging
1 program
1
PembrolizumabPhase 1/2Monoclonal Antibody
Mendus
MendusSweden - Stockholm
1 program
1
Combig-DCPhase 11 trial
Active Trials
NCT01525017CompletedEst. Dec 2013
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Behavioral InterventionN/A1 trial
Active Trials
NCT04788095Active Not RecruitingEst. Dec 2025
Ipsen
IpsenChina - Tianjin
1 program
CabozantinibN/ASmall Molecule1 trial
Active Trials
NCT06548867Recruiting80Est. Jun 2025
Bristol Myers Squibb
1 program
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaN/A
M&
Merck & Co.RAHWAY, NJ
1 program
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
NovartisEverolimus
NovartisAldesleukin
Immatics BiotechnologiesSunitinib
PfizerAxitinib
AstellasAGS-16C3F
AstellasTivozanib
PfizerPF-04856884
PfizerPF-04856884
Eli Lilly and CompanyEnzastaurin
CASI PharmaceuticalsPanzem® NCD
Providence TherapeuticsHD IL2
EisaiLenvatinib
MendusCombig-DC
IpsenCabozantinib
PfizerOutcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 1,494 patients across 16 trials

NCT01266837NovartisEverolimus

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Start: Mar 2011Est. completion: Oct 201764 patients
Phase 4Completed
NCT00414765NovartisAldesleukin

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Start: Sep 2008Est. completion: Mar 201026 patients
Phase 4Completed
NCT01265901Immatics BiotechnologiesSunitinib

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Start: Dec 2010Est. completion: Jul 2015339 patients
Phase 3Completed
NCT05817903PfizerAxitinib

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Start: Apr 2023Est. completion: Apr 2027118 patients
Phase 2Recruiting
NCT02639182AstellasAGS-16C3F

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Start: May 2016Est. completion: Oct 2020133 patients
Phase 2Completed
NCT01673386AstellasTivozanib

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

Start: Jul 2012Est. completion: Jan 201458 patients
Phase 2Terminated
NCT01441414PfizerPF-04856884

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Start: Nov 2011Est. completion: Mar 201418 patients
Phase 2Terminated
NCT01225510PfizerPF-04856884

A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma

Start: Jan 2011Est. completion: Jan 20130
Phase 2Withdrawn
NCT00709995Eli Lilly and CompanyEnzastaurin

A Study for Participants With Metastatic Renal Cell Carcinoma

Start: Jun 2008Est. completion: Sep 201817 patients
Phase 2Completed
NCT00444314CASI PharmaceuticalsPanzem® NCD

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Start: Feb 2007Est. completion: Oct 2009
Phase 2Completed
NCT00554515Providence TherapeuticsHD IL2

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma

Start: Nov 2006Est. completion: Oct 2013
Phase 2Completed
NCT01136733EisaiLenvatinib

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Start: Aug 2010Est. completion: Feb 2018173 patients
Phase 1/2Completed
NCT01525017MendusCombig-DC

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Start: Feb 2012Est. completion: Dec 2013
Phase 1Completed
NCT06548867IpsenCabozantinib

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Start: May 2024Est. completion: Jun 202580 patients
N/ARecruiting
NCT04919122PfizerOutcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Start: Apr 2022Est. completion: Dec 2026468 patients
N/AActive Not Recruiting
NCT04788095City TherapeuticsBehavioral Intervention

App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer

Start: Aug 2021Est. completion: Dec 2025
N/AActive Not Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,494 patients
14 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)